COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Zolpidem (Myslee) Post Marketing Study in Adolescent Patients With Insomnia - Evaluation With Polysomnography

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00653562
Recruitment Status : Completed
First Posted : April 7, 2008
Last Update Posted : February 17, 2017
Information provided by (Responsible Party):
Astellas Pharma Inc

Brief Summary:
To evaluate the efficacy of zolpidem for adolescent insomniacs with polysomnography

Condition or disease Intervention/treatment Phase
Insomnia Sleep Initiation and Maintenance Disorders Drug: zolpidem Phase 4

Detailed Description:
The study consists of two parts. All patients will receive placebo in one part and Zolpidem in the other part in a single blind manner. Efficacy will be measured with polysomnography .

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 11 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: Single Blind, Multi-center, Post Marketing Clinical Study of Zolpidem (Myslee) in Adolescent Patients With Insomnia - Evaluation With Polysomnography
Study Start Date : November 2006
Actual Primary Completion Date : March 2010
Actual Study Completion Date : March 2010

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: 1
Patients will receive placebo in one part and zolpidem in the other part
Drug: zolpidem
Other Name: Myslee

Primary Outcome Measures :
  1. Sleep latency [ Time Frame: 2 days ]

Secondary Outcome Measures :
  1. Total hours of sleep [ Time Frame: 2 days ]
  2. Frequency of intermediate awaking [ Time Frame: 2 days ]
  3. Time of intermediate awaking [ Time Frame: 2 days ]
  4. Patient impression [ Time Frame: 2 days ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   12 Years to 18 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients diagnosed as having nonorganic insomnia of nonorganic sleep disorder in ICD10

Exclusion Criteria:

  • Patients with schizophrenia or manic-depressive illness
  • Patients with insomnia caused by physical diseases
  • Patients having a history of hypersensitivity to zolpidem
  • Patients with attention-deficit hyperactivity disorder

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00653562

Layout table for location information
Kansai, Japan
Kantou, Japan
Kyusyu, Japan
Touhoku, Japan
Sponsors and Collaborators
Astellas Pharma Inc
Layout table for investigator information
Study Chair: Use Central Contact Astellas Pharma Inc
Additional Information:
Layout table for additonal information
Responsible Party: Astellas Pharma Inc Identifier: NCT00653562    
Other Study ID Numbers: 6199-JC-0002
First Posted: April 7, 2008    Key Record Dates
Last Update Posted: February 17, 2017
Last Verified: February 2017
Keywords provided by Astellas Pharma Inc:
Sleep disorders
Additional relevant MeSH terms:
Layout table for MeSH terms
Sleep Initiation and Maintenance Disorders
Sleep Disorders, Intrinsic
Sleep Wake Disorders
Nervous System Diseases
Mental Disorders
Sleep Aids, Pharmaceutical
Hypnotics and Sedatives
Central Nervous System Depressants
Physiological Effects of Drugs
GABA-A Receptor Agonists
GABA Agonists
GABA Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action